Neuro-Oncology News

The FDA granted fast track designation to tozuleristide for treatment of pediatric central nervous system tumors.

Continued VB-111 monotherapy priming after progression with bevacizumab combination treatment improved survival outcomes among patients with recurrent glioblastoma, according to results of a phase 1/phase 2 study published in Neuro-Oncology.

Partial or total resection appeared associated with longer OS compared with biopsy alone among a cohort of adults with brainstem high-grade gliomas, according to study results published in Journal of Neuro-Oncology.

The FDA cleared an investigational new drug application for CYNK-001, a natural killer cell therapy, for the treatment of glioblastoma multiforme.

An international study of glioblastoma revealed a cellular pathway that appears to contribute to glioma stem cell spread and proliferation.

In this guest commentary, Marcela V. Maus, MD, PhD, assistant professor of medicine at Harvard Medical School and director of cellular immunotherapy at Massachusetts General Hospital Cancer Center, discusses early research regarding the use of chimeric antigen receptor (CAR) T-cell therapy for the treatment of glioblastoma following the approval of tisagenlecleucel -T suspension ( Kymriah , Novartis), the first CAR T - cell therapy approved in the United States.

The FDA granted orphan drug designation to tesevatinib for the treatment of EGFR-positive non-small cell lung cancer, according to the drug’s manufacturer.

Hospital-based end-of-life care for elderly patients with malignant brain tumors is associated with up to $16,000 in expenses, according to a research letter published in JAMA Oncology.